ChatGPT for Clinicians Launched. UK Doctors Are Excluded.

On 23 April 2026, OpenAI launched ChatGPT for Clinicians. Two days later, OpenEvidence — the tool it most closely resembles — withdrew from the UK entirely.

UK doctors received both announcements in the same week. Neither had good news for them.

Update — June 2026: ChatGPT for Clinicians remains excluded from the UK and EEA. Nothing has changed since launch — there is no UK enrolment, and OpenAI has announced no UK timeline. The wider regulatory picture is still settling (the MHRA Medical Devices (Amendment) Regulations consultation closes 19 June 2026), so the exclusion is unlikely to lift in the near term.

What ChatGPT for Clinicians actually does

ChatGPT for Clinicians is OpenAI's attempt to bring its AI capabilities directly into clinical practice. It answers clinical questions with cited, peer-reviewed sources. Think point-of-care decision support — you ask a question, it returns a synthesised answer grounded in the medical literature.

It is, in substance, a more powerful version of what OpenEvidence was doing. And like OpenEvidence, it is currently unavailable to UK and EEA clinicians.

The exclusion is not subtle. UK doctors navigating to the product are met with a "not available in your region" message.

Why the UK is locked out

The most likely explanation is regulatory caution.

The EU AI Act classifies certain clinical AI tools as high-risk systems, with corresponding requirements around transparency, conformity assessment, and liability. The UK's own AI regulatory framework — post-Brexit and currently being shaped through the AI Opportunities Action Plan — remains unsettled. For US companies launching regulated healthcare AI products, the safest short-term decision is often to restrict access to markets where the regulatory path is clear.

The US is one of those markets. The UK currently is not.

This is the same logic that drove OpenEvidence's withdrawal. It is also the reason that UpToDate Pro Plus AI — launched with much fanfare in early 2026 — remains US and Canada only.

UK doctors are not being forgotten. They are being deliberately excluded while the regulatory picture clears.

The bar a clinical AI tool has to clear in the UK

It helps to be specific about what "regulatory caution" means here. A tool that advises on a clinical decision — answers a diagnostic or treatment question — is likely a medical device in the UK, and has to clear two separate gates. The first is MHRA medical-device registration and UKCA marking. The second, for anything deployed in the NHS, is the clinical safety standard DCB 0129 (and its deployment counterpart DCB 0160) — which requires a named clinical safety officer, a hazard log, and a documented safety case. That is a high bar, and it is the right one for software that tells a doctor what to do.

This is also why The Monday Clinical Brief sits in a different category by design. MCB summarises what was published; it does not advise on what to do with any individual patient. It is a current-awareness digest, not decision support — so it is not a medical device, and it is not affected by the regulatory pause that has shut out the Q&A tools.

The pattern UK clinicians should know about

In the space of a fortnight, two of the most prominent AI clinical tools in the world became unavailable to UK doctors:

• 23 April 2026: ChatGPT for Clinicians launches. UK and EEA excluded.
• 25 April 2026: OpenEvidence withdraws from the UK and EU.

Both tools were primarily Q&A products — you bring a clinical question, they return a referenced answer. That specific use case now has a meaningful gap in the UK market.

For clinical Q&A: what's available in the UK

iatroX is UK-based, holds MHRA registration and UKCA marking, and is actively positioning as the UK alternative for AI clinical Q&A. It does the same job as OpenEvidence and ChatGPT for Clinicians — referenced answers to point-of-care questions — within a UK regulatory framework.

It is not a perfect substitute. These tools differ in model quality, citation depth, and interface. But it is the most credible UK-regulatory-compliant option in this space right now.

The other half of the problem

Clinical Q&A tools solve a specific problem: you have a question, you need a referenced answer, you get one quickly.

What they do not solve — and what is easy to overlook in the noise around these launches and withdrawals — is the problem of staying current.

A practice-changing trial published last week does not appear in any Q&A tool until you already know to ask about it. The gap between what was published and what you know exists, whether or not ChatGPT for Clinicians is available in your region.

That is the problem we built The Monday Clinical Brief to address.

What The Monday Clinical Brief offers

Every Monday morning, we send you every new peer-reviewed paper published that week in the five highest-impact journals in your specialty. Plain-language summaries. Links to the originals. Nothing else.

We cover 31 specialties. We do the curation. You stay current.

£20 a year. No app. No regulatory uncertainty. Just your inbox.

Subscribe to The Monday Clinical Brief — and know what's new before anyone asks you about it.

The bottom line

ChatGPT for Clinicians is not coming to the UK any time soon. Neither, for now, is OpenEvidence. For clinical Q&A in the meantime, iatroX is the most credible UK option.

But neither of those tools — available or not — tells you what was published last week. That is a different job. And it matters just as much.

Related reading

• Looking for an OpenEvidence alternative in the UK?
• Heidi Evidence is excellent — and in the UK it won't answer mid-consultation